
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra is a market leader in the medical device industry, with a strong portfolio of innovative products that are aimed at improving treatment outcomes for patients with vascular diseases. They have a diverse product portfolio and continue to grow and expand internationally. While there is some overlap with Boston Scientific, we do not anticipate antitrust issues and believe the premium price of the acquisition is warranted due to Penumbra's strong growth and profitability. However, there are potential risks such as ongoing litigation and integration issues with M&A activity.
Bears say
Penumbra is a growing company in the thrombectomy space, with strong revenue growth and high operating margins. However, the recent acquisition deal by Boston Scientific raises concerns about competitive pressures and the potential for penetration by larger, well-established players with greater resources. Additionally, risks such as regulatory approvals and changes in reimbursement could negatively impact the company's performance. There is also concern about potential challenges in competing against these established players in the marketplace.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares